Clinical trials: Glaucoma,Open-Angle
Open-angle Glaucoma
Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.
- Trial name
- NCT00451152
- Testing
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
The purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.
- Trial name
- NCT01340014
- Testing
- Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Performance of the Travoprost Intraocular Implant
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid…
- Trial name
- NCT06582732
- Testing
- Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6
- Where
- Armenia
- Volunteers
- 210 people
- Sponsor
- Glaukos Corporation
Glaucoma
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle…
- Trial name
- NCT01514721
- Testing
- Travoprost/Timolol Maleate BAK-Free Fixed Combination
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma (POAG)
Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.
- Trial name
- NCT01252849
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
- Trial name
- NCT06223048
- Testing
- AMDX-2011P
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amydis Inc.
Primary Open-angle Glaucoma
PRESERFLO® MicroShunt Extension Study
This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with…
- Trial name
- NCT04333433
- Testing
- PRESERFLO® MicroShunt, Trabeculectomy
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 279 people
- Sponsor
- InnFocus Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00372931
- Testing
- AL-37807
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
- Trial name
- NCT01896180
- Testing
- ALZ-1101, Latanoprost
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Alleanza Pharmaceuticals, Inc.
Primary Open-angle Glaucoma, Ocular Hypertension
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT00372827
- Testing
- Brinzolamide 1% added to Travoprost 0.004%
- Where
- Germany
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle…
- Trial name
- NCT00892762
- Testing
- Travoprost APS 40 micrograms/ml eye drop solution, Latanoprost 50 micrograms/ml eye drop solution
- Volunteers
- 434 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE SURGICAL SYSTEM in Patients With Open-Angle Glaucoma
A prospective, nonrandomized, open label study to evaluate the safety and IOP lowering effectiveness of the Streamline Surgical System, in patients with mild-to-moderate open angle glaucoma undergoing cataract surgery.
- Trial name
- NCT05089474
- Testing
- Streamline Surgical System
- Where
- 3 sites in Costa Rica, Dominican Republic and 1 more
- Volunteers
- 45 people
- Sponsor
- New World Medical, Inc.
Glaucoma, Open Angle, Ocular Hypertension
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
- Trial name
- NCT00219596
- Testing
- Xalacom, unfixed Latanoprost and Timolol
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
Adherence Assessment With Travalert Dosing Aid
The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.
- Trial name
- NCT00508469
- Testing
- Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav), Travoprost 0.004% eye drops, Timolol 0.05% eye drops
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Alcon Research
Glaucoma Primary Open Angle
Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
The objective of this phase IV clinical multi-center trial will be to compare the efficacy and safety of Ganforti® versus Krytantek®, using a cross-over design during a six month period (including a one-month wash-in period) in…
- Trial name
- NCT01737853
- Testing
- Ganforti, Krytantek
- Where
- 4 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Allergan S.A. DE C.V..
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.